1887

Abstract

At present, infections with bovine viral diarrhea virus (BVDV) type 2 occur nearly as frequently as those with BVDV type 1, so development of vaccines that protect cattle from both type 1 and type 2 BVDV has become critical. In this study, we compared various DNA prime–protein boost vaccination strategies to protect cattle from challenge with BVDV-2 using the major protective antigen of BVDV, glycoprotein E2. Calves were immunized with a plasmid encoding either type 1 E2 (E2.1) or type 2 E2 (E2.2) or with both plasmids (E2.1+E2.2). This was followed by a heterologous boost with E2.1, E2.2 or E2.1 and E2.2 protein formulated with Emulsigen and a CpG oligodeoxynucleotide. Subsequently, the calves were challenged with BVDV-2 strain 1373. All vaccinated calves developed both humoral and cell-mediated immune responses, including virus-neutralizing antibodies and IFN--secreting cells in the peripheral blood. Depletion studies showed that CD4 T cells were responsible for IFN- production. Furthermore, the calves vaccinated with either the E2.2 or the E2.1+E2.2 vaccines were very well protected from challenge with BVDV-2, having little leukopenia and showing no weight loss or temperature response. In addition, the animals vaccinated with the E2.1 vaccine were partially protected, so there was a certain level of cross-protection. These data demonstrate that a vaccination strategy consisting of priming with E2.2 or E2.1+E2.2 DNA and boosting with E2.2 or E2.1+E2.2 protein fully protects cattle from BVDV-2 challenge.

Loading

Article metrics loading...

/content/journal/jgv/10.1099/vir.0.83251-0
2008-02-01
2019-11-19
Loading full text...

Full text loading...

/deliver/fulltext/jgv/89/2/453.html?itemId=/content/journal/jgv/10.1099/vir.0.83251-0&mimeType=html&fmt=ahah

References

  1. Anson, D. S. ( 2004; ). The use of retroviral vectors for gene therapy-what are the risks? A review of retroviral pathogenesis and its relevance to retroviral vector-mediated gene delivery. Genet Vaccines Ther 2, 9 [CrossRef]
    [Google Scholar]
  2. Baker, J. C. ( 1995; ). The clinical manifestations of bovine viral diarrhea infection. Vet Clin North Am Food Anim Pract 11, 425–445.
    [Google Scholar]
  3. Barnett, S. W., Rajasekar, S., Legg, H., Doe, B., Fuller, D. H., Haynes, J. R., Walker, C. M. & Steimer, K. S. ( 1997; ). Vaccination with HIV-1 gp120 DNA induces immune responses that are boosted by a recombinant gp120 protein subunit. Vaccine 15, 869–873.[CrossRef]
    [Google Scholar]
  4. Bolin, S. R. & Ridpath, J. F. ( 1992; ). Differences in virulence between two noncytopathic bovine viral diarrhea viruses in calves. Am J Vet Res 53, 2157–2163.
    [Google Scholar]
  5. Bolin, S. R. & Ridpath, J. F. ( 1998; ). Prevalence of bovine viral diarrhea virus genotypes and antibody against those viral genotypes in fetal bovine serum. J Vet Diagn Invest 10, 135–139.[CrossRef]
    [Google Scholar]
  6. Braun, R., Babiuk, L. A. & van Drunen Littel-van den Hurk, S. ( 1998; ). Compatibility of plasmids expressing different antigens in a single DNA vaccine formulation. J Gen Virol 79, 2965–2970.
    [Google Scholar]
  7. Brownlie, J., Clarke, M. C., Hooper, L. B. & Bell, G. D. ( 1995; ). Protection of the bovine fetus from bovine viral diarrhoea virus by means of a new inactivated vaccine. Vet Rec 137, 58–62.[CrossRef]
    [Google Scholar]
  8. Canal, C. W., Strasser, M., Hertig, C., Masuda, A. & Peterhans, E. ( 1998; ). Detection of antibodies to bovine viral diarrhoea virus (BVDV) and characterization of genomes of BVDV from Brazil. Vet Microbiol 63, 85–97.[CrossRef]
    [Google Scholar]
  9. Cardoso, A. I., Sixt, N., Vallier, A., Fayolle, J., Buckland, R. & Wild, T. F. ( 1998; ). Measles virus DNA vaccination: antibody isotype is determined by the method of immunization and by the nature of both the antigen and the coimmunized antigen. J Virol 72, 2516–2518.
    [Google Scholar]
  10. Collett, M. S., Larson, R., Belzer, S. K. & Retzel, E. ( 1988; ). Proteins encoded by bovine viral diarrhea virus: the genomic organization of a pestivirus. Virology 165, 200–208.[CrossRef]
    [Google Scholar]
  11. Collett, M. S., Wiskerchen, M., Welniak, E. & Belzer, S. K. ( 1991; ). Bovine viral diarrhea virus genomic organization. Arch Virol Suppl 3, 19–27.
    [Google Scholar]
  12. Couvreur, B., Letellier, C., Collard, A., Quenon, P., Dehan, P., Hamers, C., Pastoret, P. P. & Kerkhofs, P. ( 2002; ). Genetic and antigenic variability in bovine viral diarrhea virus (BVDV) isolates from Belgium. Virus Res 85, 17–28.[CrossRef]
    [Google Scholar]
  13. Dean, H. J. & Leyh, R. ( 1999; ). Cross-protective efficacy of a bovine viral diarrhea virus (BVDV) type 1 vaccine against BVDV type 2 challenge. Vaccine 17, 1117–1124.[CrossRef]
    [Google Scholar]
  14. Dunachie, S. J., Walther, M., Vuola, J. M., Webster, D. P., Keating, S. M., Berthoud, T., Andrews, L., Bejon, P., Poulton, I. & other authors ( 2006; ). A clinical trial of prime–boost immunisation with the candidate malaria vaccines RTS,S/AS02A and MVA-CS. Vaccine 24, 2850–2859.[CrossRef]
    [Google Scholar]
  15. Ellis, J., West, K., Cortese, V., Konoby, C. & Weigel, D. ( 2001; ). Effect of maternal antibodies on induction and persistence of vaccine-induced immune responses against bovine viral diarrhea virus type II in young calves. J Am Vet Med Assoc 219, 351–356.[CrossRef]
    [Google Scholar]
  16. Ellsworth, M. A., Fairbanks, K. K., Behan, S., Jackson, J. A., Goodyear, M., Oien, N. L., Meinert, T. R. & Leyh, R. D. ( 2006; ). Fetal protection following exposure to calves persistently infected with bovine viral diarrhea virus type 2 sixteen months after primary vaccination of the dams. Vet Ther 7, 295–304.
    [Google Scholar]
  17. Evermann, J. F. & Ridpath, J. F. ( 2002; ). Clinical and epidemiologic observations of bovine viral diarrhea virus in the northwestern United States. Vet Microbiol 89, 129–139.[CrossRef]
    [Google Scholar]
  18. Fairbanks, K. K., Rinehart, C. L., Ohnesorge, W. C., Loughin, M. M. & Chase, C. C. ( 2004; ). Evaluation of fetal protection against experimental infection with type 1 and type 2 bovine viral diarrhea virus after vaccination of the dam with a bivalent modified-live virus vaccine. J Am Vet Med Assoc 225, 1898–1904.[CrossRef]
    [Google Scholar]
  19. Ficken, M. D., Ellsworth, M. A. & Tucker, C. M. ( 2006a; ). Evaluation of the efficacy of a modified-live combination vaccine against bovine viral diarrhea virus types 1 and 2 challenge exposures in a one-year duration-of-immunity fetal protection study. Vet Ther 7, 283–294.
    [Google Scholar]
  20. Ficken, M. D., Ellsworth, M. A., Tucker, C. M. & Cortese, V. S. ( 2006b; ). Effects of modified-live bovine viral diarrhea virus vaccines containing either type 1 or types 1 and 2 BVDV on heifers and their offspring after challenge with noncytopathic type 2 BVDV during gestation. J Am Vet Med Assoc 228, 1559–1564.[CrossRef]
    [Google Scholar]
  21. Fulton, R. W. & Burge, L. J. ( 2000; ). Bovine viral diarrhea virus types 1 and 2 antibody response in calves receiving modified live virus or inactivated vaccines. Vaccine 19, 264–274.[CrossRef]
    [Google Scholar]
  22. Fulton, R. W., Johnson, B. J., Briggs, R. E., Ridpath, J. F., Saliki, J. T., Confer, A. W., Burge, L. J., Step, D. L., Walker, D. A. & Payton, M. E. ( 2006; ). Challenge with bovine viral diarrhea virus by exposure to persistently infected calves: protection by vaccination and negative results of antigen testing in nonvaccinated acutely infected calves. Can J Vet Res 70, 121–127.
    [Google Scholar]
  23. Galloway, D., Liner, A., Legutki, J., Mateczun, A., Barnewall, R. & Estep, J. ( 2004; ). Genetic immunization against anthrax. Vaccine 22, 1604–1608.[CrossRef]
    [Google Scholar]
  24. Hamers, C., Couvreur, B., Dehan, P., Letellier, C., Fischer, L., Brun, A. J., Lewalle, P., Michaux, C., Pastoret, P. P. & Kerkhofs, P. ( 2003; ). Assessment of the clinical and virological protection provided by a commercial inactivated bovine viral diarrhoea virus genotype 1 vaccine against a BVDV genotype 2 challenge. Vet Rec 153, 236–240.[CrossRef]
    [Google Scholar]
  25. Houe, H. ( 1995; ). Epidemiology of bovine viral diarrhea virus. Vet Clin North Am Food Anim Pract 11, 521–547.
    [Google Scholar]
  26. Kim, I. J., Hyun, B. H., Shin, J. H., Lee, K. K., Lee, K. W., Cho, K. O. & Kang, M. I. ( 2006; ). Identification of bovine viral diarrhea virus type 2 in Korean native goat (Capra hircus). Virus Res 121, 103–106.[CrossRef]
    [Google Scholar]
  27. Kong, W. P., Huang, Y., Yang, Z. Y., Chakrabarti, B. K., Moodie, Z. & Nabel, G. J. ( 2003; ). Immunogenicity of multiple gene and clade human immunodeficiency virus type 1 DNA vaccines. J Virol 77, 12764–12772.[CrossRef]
    [Google Scholar]
  28. Konishi, E., Kosugi, S. & Imoto, J. ( 2006; ). Dengue tetravalent DNA vaccine inducing neutralizing antibody and anamnestic responses to four serotypes in mice. Vaccine 24, 2200–2207.[CrossRef]
    [Google Scholar]
  29. Kovacs, F., Magyar, T., Rinehart, C., Elbers, K., Schlesinger, K. & Ohnesorge, W. C. ( 2003; ). The live attenuated bovine viral diarrhea virus components of a multi-valent vaccine confer protection against fetal infection. Vet Microbiol 96, 117–131.[CrossRef]
    [Google Scholar]
  30. Li, Z., Zhang, H., Fan, X., Zhang, Y., Huang, J., Liu, Q., Tjelle, T. E., Mathiesen, I., Kjeken, R. & Xiong, S. ( 2006; ). DNA electroporation prime and protein boost strategy enhances humoral immunity of tuberculosis DNA vaccines in mice and non-human primates. Vaccine 24, 4565–4568.[CrossRef]
    [Google Scholar]
  31. Liang, R., van den Hurk, J. V., Zheng, C., Yu, H., Pontarollo, R. A., Babiuk, L. A. & van Drunen Littel-van den Hurk, S. ( 2005; ). Immunization with plasmid DNA encoding a truncated, secreted form of the bovine viral diarrhea virus E2 protein elicits strong humoral and cellular immune responses. Vaccine 23, 5252–5262.[CrossRef]
    [Google Scholar]
  32. Liang, R., van den Hurk, J. V., Babiuk, L. A. & van Drunen Littel-van den Hurk, S. ( 2006; ). Priming with DNA encoding E2 and boosting with E2 protein formulated with CpG oligodeoxynucleotides induces strong immune responses and protection from bovine viral diarrhea virus in cattle. J Gen Virol 87, 2971–2982.[CrossRef]
    [Google Scholar]
  33. Lu, S. ( 2006; ). Combination DNA plus protein HIV vaccines. Springer Semin Immunopathol 28, 255–265.[CrossRef]
    [Google Scholar]
  34. Martin, J. E., Sullivan, N. J., Enama, M. E., Gordon, I. J., Roederer, M., Koup, R. A., Bailer, R. T., Chakrabarti, B. K., Bailey, M. A. & other authors ( 2006; ). A DNA vaccine for Ebola virus is safe and immunogenic in a phase I clinical trial. Clin Vaccine Immunol 13, 1267–1277.[CrossRef]
    [Google Scholar]
  35. McConkey, S. J., Reece, W. H., Moorthy, V. S., Webster, D., Dunachie, S., Butcher, G., Vuola, J. M., Blanchard, T. J., Gothard, P. & other authors ( 2003; ). Enhanced T-cell immunogenicity of plasmid DNA vaccines boosted by recombinant modified vaccinia virus Ankara in humans. Nat Med 9, 729–735.[CrossRef]
    [Google Scholar]
  36. Moore, Q. C., Bosarge, J. R., Quin, L. R. & McDaniel, L. S. ( 2006; ). Enhanced protective immunity against pneumococcal infection with PspA DNA and protein. Vaccine 24, 5755–5761.[CrossRef]
    [Google Scholar]
  37. Mwau, M., Cebere, I., Sutton, J., Chikoti, P., Winstone, N., Wee, E. G., Beattie, T., Chen, Y. H., Dorrell, L. & other authors ( 2004; ). A human immunodeficiency virus 1 (HIV-1) clade A vaccine in clinical trials: stimulation of HIV-specific T-cell responses by DNA and recombinant modified vaccinia virus Ankara (MVA) vaccines in humans. J Gen Virol 85, 911–919.[CrossRef]
    [Google Scholar]
  38. Nakamura, Y., Gojobori, T. & Ikemura, T. ( 2000; ). Codon usage tabulated from international DNA sequence databases: status for the year 2000. Nucleic Acids Res 28, 292 [CrossRef]
    [Google Scholar]
  39. O'Hagan, D. T., Singh, M. & Ulmer, J. B. ( 2006; ). Microparticle-based technologies for vaccines. Methods 40, 10–19.[CrossRef]
    [Google Scholar]
  40. Pal, R., Kalyanaraman, V. S., Nair, B. C., Whitney, S., Keen, T., Hocker, L., Hudacik, L., Rose, N., Mboudjeka, I. & other authors ( 2006; ). Immunization of rhesus macaques with a polyvalent DNA prime/protein boost human immunodeficiency virus type 1 vaccine elicits protective antibody response against simian human immunodeficiency virus of R5 phenotype. Virology 348, 341–353.[CrossRef]
    [Google Scholar]
  41. Pellerin, C., van den Hurk, J., Lecomte, J. & Tussen, P. ( 1994; ). Identification of a new group of bovine viral diarrhea virus strains associated with severe outbreaks and high mortalities. Virology 203, 260–268.[CrossRef]
    [Google Scholar]
  42. Pratelli, A., Martella, V., Cirone, F., Buonavoglia, D., Elia, G., Tempesta, M. & Buonavoglia, C. ( 2001; ). Genomic characterization of pestiviruses isolated from lambs and kids in southern Italy. J Virol Methods 94, 81–85.[CrossRef]
    [Google Scholar]
  43. Raggo, C., Habermehl, M., Babiuk, L. A. & Griebel, P. ( 2000; ). The in vivo effects of recombinant bovine herpesvirus-1 expressing bovine interferon-γ. J Gen Virol 81, 2665–2673.
    [Google Scholar]
  44. Reber, A. J., Tanner, M., Okinaga, T., Woolums, A. R., Williams, S., Ensley, D. T. & Hurley, D. J. ( 2006; ). Evaluation of multiple immune parameters after vaccination with modified live or killed bovine viral diarrhea virus vaccines. Comp Immunol Microbiol Infect Dis 29, 61–77.[CrossRef]
    [Google Scholar]
  45. Ridpath, J. F. ( 2005; ). Practical significance of heterogeneity among BVDV strains: impact of biotype and genotype on US control programs. Prev Vet Med 72, 17–30 (discussion 215–219).[CrossRef]
    [Google Scholar]
  46. Ridpath, J. F., Bolin, S. R. & Dubovi, E. J. ( 1994; ). Segregation of bovine viral diarrhea virus into genotypes. Virology 205, 66–74.[CrossRef]
    [Google Scholar]
  47. Sedegah, M., Charoenvit, Y., Minh, L., Belmonte, M., Majam, V. F., Abot, S., Ganeshan, H., Kumar, S., Bacon, D. J. & other authors ( 2004; ). Reduced immunogenicity of DNA vaccine plasmids in mixtures. Gene Ther 11, 448–456.[CrossRef]
    [Google Scholar]
  48. Shimazaki, T., Sekiguchi, H., Nakamura, S., Taguchi, K., Inoue, Y. & Satoh, M. ( 1998; ). Segregation of bovine viral diarrhea virus isolated in Japan into genotypes. J Vet Med Sci 60, 579–583.[CrossRef]
    [Google Scholar]
  49. Shiver, J. W., Fu, T. M., Chen, L., Casimiro, D. R., Davies, M. E., Evans, R. K., Zhang, Z. Q., Simon, A. J., Trigona, W. L. & other authors ( 2002; ). Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity. Nature 415, 331–335.[CrossRef]
    [Google Scholar]
  50. van Oirschot, J. T., Bruschke, C. J. & van Rijn, P. A. ( 1999; ). Vaccination of cattle against bovine viral diarrhoea. Vet Microbiol 64, 169–183.[CrossRef]
    [Google Scholar]
  51. Vilcek, S., Paton, D. J., Durkovic, B., Strojny, L., Ibata, G., Moussa, A., Loitsch, A., Rossmanith, W., Vega, S. & other authors ( 2001; ). Bovine viral diarrhoea virus genotype 1 can be separated into at least eleven genetic groups. Arch Virol 146, 99–115.[CrossRef]
    [Google Scholar]
  52. Vilcek, S., Greiser-Wilke, I., Durkovic, B., Obritzhauser, W., Deutz, A. & Kofer, J. ( 2003; ). Genetic diversity of recent bovine viral diarrhoea viruses from the southeast of Austria (Styria). Vet Microbiol 91, 285–291.[CrossRef]
    [Google Scholar]
  53. Vilcek, S., Durkovic, B., Kolesarova, M. & Paton, D. J. ( 2005; ). Genetic diversity of BVDV: consequences for classification and molecular epidemiology. Prev Vet Med 72, 31–35 (discussion 215–219).[CrossRef]
    [Google Scholar]
  54. Wakeley, P. R., Turner, J. L., Ibata, G., King, D. P., Sandvik, T., Howard, P. & Drew, T. W. ( 2004; ). Characterisation of a type 2 bovine viral diarrhoea virus isolated from cattle in the UK. Vet Microbiol 102, 19–24.[CrossRef]
    [Google Scholar]
  55. Waldvogel, A. S., Hediger-Weithaler, B. M., Eicher, R., Zakher, A., Zarlenga, D. S., Gasbarre, L. C. & Heussler, V. T. ( 2000; ). Interferon-γ and interleukin-4 mRNA expression by peripheral blood mononuclear cells from pregnant and non-pregnant cattle seropositive for bovine viral diarrhea virus. Vet Immunol Immunopathol 77, 201–212.[CrossRef]
    [Google Scholar]
  56. Webster, D. P., Dunachie, S., McConkey, S., Poulton, I., Moore, A. C., Walther, M., Laidlaw, S. M., Peto, T., Skinner, M. A. & other authors ( 2006; ). Safety of recombinant fowlpox strain FP9 and modified vaccinia virus Ankara vaccines against liver-stage P. falciparum malaria in non-immune volunteers. Vaccine 24, 3026–3034.[CrossRef]
    [Google Scholar]
  57. Wolfmeyer, A., Wolf, G., Beer, M., Strube, W., Hehnen, H. R., Schmeer, N. & Kaaden, O. R. ( 1997; ). Genomic (5′UTR) and serological differences among German BVDV field isolates. Arch Virol 142, 2049–2057.[CrossRef]
    [Google Scholar]
  58. Yu, H., Babiuk, L. A. & van Drunen Littel-van den Hurk, S. ( 2004; ). Priming with CpG-enriched plasmid and boosting with protein formulated with CpG oligodeoxynucleotides and Quil A induces strong cellular and humoral immune responses to hepatitis C virus NS3. J Gen Virol 85, 1533–1543.[CrossRef]
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jgv/10.1099/vir.0.83251-0
Loading
/content/journal/jgv/10.1099/vir.0.83251-0
Loading

Data & Media loading...

Most Cited This Month

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error